. home.aspx



GSK aims to get triple therapy approved for asthma in US

October 03, 2019 / Richard Staines

GlaxoSmithKline and development partner Innoviva have filed a dossier with the FDA, in a bid to get their triple therapy approved to keep asthma at bay. Trelegy (fluticasone furoate/umeclidinium/vilanterol) is already marketed in the US in chronic obstructive pulmonary disease (COPD) – but GSK is chasing this additional indication as an asthma maintenance therapy as it seeks to find a successor to its ageing respiratory drug Advair (fluticasone propionate+salmeterol). Advair is finally losing sales to generic competitors after the FDA finally approved a cheaper rival from Mylan earlier this year, following years of delays because of the regulator’s demanding technical requirements for drug-device combinations. Already approved in COPD, GSK is aiming to get its triple therapy approved in the highly competitive US market. Aside from generic Advair there are a range of other treatments available including injections from GSK, AstraZeneca and Sanofi that aim to reduce the infla...